Compare Enveric Biosciences Inc (ENVB) vs PAGSEG Inc (PAGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs PAGSEG Inc — how do they compare? Enveric Biosciences Inc trades at $1.51 (market cap $6.69M), while PAGSEG Inc trades at $10.65 (market cap $2.90B). The key difference: PAGSEG Inc is far larger — about 433.5× Enveric Biosciences Inc's market cap, and PAGSEG Inc pays a 10.66% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Enveric Biosciences Inc for 14 Days and PAGSEG Inc for 26 Days on average.
| ENVB | PAGS | |
|---|---|---|
Market Cap | $6.69M | $2.90B |
Volume | 41,141 | 4,931,855 |
Sector | Health | Industrials |
52-Week High | $10.80 | $12.00 |
52-Week Low | $1.27 | $8.44 |
Typical Hold Time | 14 Days | 26 Days |
Enterprise Value | -$1.60M | $11.04B |
Dividend Yield | — | 10.66% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.495, up 1.7% on the day, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. The company reported no revenue in 2025 and a net loss of $8.77 million, though it has consistently beaten EPS expectations. Recent news includes a new U.S. patent allowance for its non-hallucinogenic mescaline derivatives and participation in an investment conference.
The outlook remains speculative given the lack of revenue and negative profitability, but analyst consensus is bullish with 75% buy ratings. Key risks include the pre-revenue biotech model and dependence on successful drug development. Upside potential hinges on clinical progress and regulatory milestones for its psychiatric therapeutics pipeline.
PAGS trades at $10.51, down 1.96% on the day, with a bullish technical signal from moving averages. The stock shows strong fundamentals with a P/E of 7 and net income margin of 10.45%, supported by recent earnings beats. A dividend of $0.28 is scheduled for September 2026. Analyst consensus is bullish with a $10.70 price target, though RSI levels indicate potential overbought conditions near-term.
The outlook for PAGS is positive given its undervalued metrics and profitability, but risks include macroeconomic pressures in Brazil and elevated credit losses. Institutional interest remains strong, with recent buys from Bank of America. The stock presents a value opportunity with dividend income, though investors should monitor earnings consistency and interest rate impacts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About PAGSEG Inc
PagSeguro Digital Ltd. is a leading provider of financial technology solutions in Brazil, primarily focused on e-commerce, face-to-face transactions, and financial services. The company's main offerings include PagBank, a digital banking platform, and PagSeguro, a suite of payment processing solutions that includes point-of-sale devices and online payment gateways. PAGS targets micro-merchants, small and medium-sized enterprises (SMEs), and consumers, aiming to democratize access to financial services in the country.
Read more on PAGS →
